RNA(RNA)
RNA
Q4 2026 EPS Estimate
$-0.87
Nov 12, 2026
Revenue Estimate
$15M
Analyst Sentiment
Wall St. Consensus
Buy15 analysts·Moderate coverage
63
Score
8 Buy (53%)7 Hold (47%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
853%
Hold
747%
Sell
00%
Strong Sell
00%
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price Target Expectations
Bear
$25.00
+161.2%
Consensus
$25.00
+161.2%
Bull
$25.00
+161.2%
12-Month Target Range15 analysts
$25.00$25.00$25.00
Current $9.57Consensus
Current Price
$9.57
Upside to Consensus
$15.43
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
Earnings & Revenue Estimates
Forward Growth Estimates (YoY)
FY2027
Rev-88.36%
EPS—
FY2028
Rev+0.00%
EPS—
FY2029
Rev+40123.39%
EPS—
Raw consensus estimates (low / average / high) from covering analysts.
Annual
| Metric | FY2026E | FY2027E | FY2028E | FY2029E | FY2030E |
|---|---|---|---|---|---|
| Revenue Avg | $34M | $4M | $4M | $1.61B | $19M |
| Low | $20M | $2M | $2M | $941M | $11M |
| High | $48M | $6M | $6M | $2.26B | $26M |
| EBITDA Avg | $-77M | $-121M | $-111M | $-65M | $-65M |
| Low | $-86M | $-122M | $-115M | $-112M | $-109M |
| High | $-69M | $-120M | $-107M | $-16M | $-19M |
| EBIT Avg | $-78M | $-121M | $-112M | $-90M | $-85M |
| Low | $-86M | $-122M | $-116M | $-138M | $-130M |
| High | $-70M | $-121M | $-108M | $-42M | $-39M |
| Net Income Avg | $-78M | $-121M | $-112M | $-90M | $-85M |
| Low | $-86M | $-122M | $-116M | $-138M | $-130M |
| High | $-70M | $-121M | $-108M | $-42M | $-39M |
| EPS Avg | $-4.58 | $-7.10 | $-6.53 | $-5.27 | $-4.98 |
| Low | $-5.05 | $-7.14 | $-6.76 | $-8.04 | $-7.60 |
| High | $-4.10 | $-7.05 | $-6.31 | $-2.43 | $-2.29 |
| Analysts (Rev / EPS) | 3 / 2 | 3 / 2 | 2 / 2 | 1 / 1 | 1 / 1 |
Quarterly
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|
| Revenue Avg | $15M | $1M | $3M | $3M | $3M | $3M |
| Low | $15M | $1M | $3M | $3M | $3M | $3M |
| High | $15M | $1M | $3M | $3M | $3M | $3M |
| EBITDA Avg | $-14M | $-26M | $-29M | $-29M | $-31M | $-31M |
| Low | $-14M | $-26M | $-29M | $-29M | $-31M | $-31M |
| High | $-14M | $-26M | $-29M | $-29M | $-31M | $-31M |
| EBIT Avg | $-15M | $-27M | $-29M | $-30M | $-31M | $-32M |
| Low | $-15M | $-27M | $-29M | $-30M | $-31M | $-32M |
| High | $-15M | $-27M | $-29M | $-30M | $-31M | $-32M |
| Net Income Avg | $-15M | $-27M | $-29M | $-30M | $-31M | $-32M |
| Low | $-15M | $-27M | $-29M | $-30M | $-31M | $-32M |
| High | $-15M | $-27M | $-29M | $-30M | $-31M | $-32M |
| EPS Avg | $-0.87 | $-1.55 | $-1.69 | $-1.73 | $-1.81 | $-1.86 |
| Low | $-0.87 | $-1.55 | $-1.69 | $-1.73 | $-1.81 | $-1.86 |
| High | $-0.87 | $-1.55 | $-1.69 | $-1.73 | $-1.81 | $-1.86 |
| Analysts (Rev / EPS) | 4 / 1 | 4 / 1 | 2 / 1 | 2 / 1 | 2 / 1 | 2 / 1 |
